Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hightide Therapeutics Inc ( (HK:2511) ) has provided an announcement.
HighTide Therapeutics, Inc. has successfully completed the placing of 56,555,000 new shares, raising approximately HK$123.4 million in net proceeds. The funds will be used for the clinical development and commercialization of HTD1801, enhancing the company’s pipeline and market position in the biopharmaceutical industry.
More about Hightide Therapeutics Inc
HighTide Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for metabolic and digestive diseases. The company’s lead compound, HTD1801, is a first-in-class, gut-liver anti-inflammatory metabolic modulator.
Average Trading Volume: 2,864,684
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$1.4B
Learn more about 2511 stock on TipRanks’ Stock Analysis page.